Recursion — Third Quarter 2026 Earnings Summary

Recursion Pharmaceuticals reported third-quarter 2026 financial results showing a net loss of $119.0 million and total revenue of $18.6 million, driven by a $10 million milestone payment from Sanofi. The company announced positive Phase 2 data for its lead candidate REC-4881 in familial adenomatous polyposis, demonstrating deep and durable reductions in polyp burden across the gastrointestinal tract, alongside early clinical signals for REC-1245 in endometrial and liver cancers. Financially, Recursion extended its cash runway into 2029 following an October 2026 follow-on offering and reiterated 2026 cash operating expense guidance of less than $375 million. Additionally, the company appointed Fred Hassan as Chair of the Board and confirmed that Sanofi has optioned a first-in-class immunology development candidate from their collaboration.